#AS­CO22: Un­con­cerned with lat­er mar­ket en­try, Ar­cel­lx on the up with new BC­MA CAR-T da­ta

Ar­cel­lx $ACLX has been trad­ing up more than 25% in the last five days, thanks to an AS­CO ab­stract for its Phase I tri­al for its CAR-T ther­a­py for mul­ti­ple myelo­ma. Now, the biotech is ready to re­veal an up­dat­ed pic­ture.

The ex­pand­ed re­sults on its BC­MA-tar­get­ing CAR-T ther­a­py in­clude 31 pa­tients, 16 of which have fol­low-up da­ta for at least one year. Of the 16 pa­tients with 12-month da­ta, 13 showed a com­plete re­sponse to Ar­cel­lx’s ther­a­py — a CR rate of 81%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER